The Kidney Disease: Improving Global Outcomes (KDIGO) 2020 guideline informs the management of patients with diabetes and chronic kidney disease.

An update from KDIGO, an independent organization that aims to improve the care of patients with kidney disease worldwide. A layered approach is recommended while caring for patients with diabetes ...

Improving Global Outcomes (KDIGO) group has updated chronic kidney disease treatment guidelines to help slow disease progression in adults. A JAMA article published Wednesday summarized the revised ...

The KDIGO 2021 blood pressure guidance for patients with kidney disease not receiving dialysis significantly updates recommendations issued in 2012.

Updated guidelines include 13 recommendations and 52 practice points for clinicians treating patients with diabetes and chronic kidney disease (CKD).

Mundipharma Welcomes the New 2020 Clinical Practice Guideline from KDIGO recommending SGLT2is alongside metformin as first-line anti-hyperglycaemic therapy in type 2 diabetes patients with chronic ...

References: KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.

The 2021 KDIGO BP Guideline specifies systolic BP of less than 120 mm Hg (by standardized measure, above) as the ideal target for patients with CKD, either with or without diabetes, as long as ...

New CKD in a Patient With Diabetes: What to Do? Applying the KDIGO Clinical Practice Guideline for Diabetes Management in CKD Jay H. Shubrook, DO Disclosures January 26, 2021 0 ...

The latest clinical practice guideline from the Kidney Disease: Improving Global Outcomes (KDIGO) organization offers advice for treating patients with diabetes and chronic kidney disease (CKD). A ...

The new clinical guidelines recommend finerenone for patients with CKD associated with T2D and an eGFR of ≥25 mL/min/1.73 m 2, as well as normal serum potassium concentration and albuminuria ...